Chikungunya
Product
Emergent BioSolutions Inc.
Total Payments
$1.4M
Transactions
43
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $1.4M | 43 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 43 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0328 | Emergent BioSolutions Inc. | $197,467 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0327 | Emergent BioSolutions Inc. | $182,505 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0329 | Emergent BioSolutions Inc. | $161,741 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | Emergent BioSolutions Inc. | $111,443 | 1 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0325 | Emergent BioSolutions Inc. | $107,060 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0319 | Emergent BioSolutions Inc. | $101,442 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0332 | Emergent BioSolutions Inc. | $89,074 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0330 | Emergent BioSolutions Inc. | $81,823 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0323 | Emergent BioSolutions Inc. | $70,433 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0333 | Emergent BioSolutions Inc. | $68,179 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0321 | Emergent BioSolutions Inc. | $57,391 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0331 | Emergent BioSolutions Inc. | $50,713 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0320 | Emergent BioSolutions Inc. | $41,127 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0324 | Emergent BioSolutions Inc. | $15,832 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0326 | Emergent BioSolutions Inc. | $12,940 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0335 | Emergent BioSolutions Inc. | $10,086 | 0 |
| PXVX-CV-317-001: A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], unadjuvanted or alum-adjuvanted) | Emergent BioSolutions Inc. | $7,525 | 1 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0322 | Emergent BioSolutions Inc. | $4,346 | 0 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0318 | Emergent BioSolutions Inc. | $2,898 | 0 |
| EBSI-CV-317-004: A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents | Emergent BioSolutions Inc. | $2,800 | 1 |
Top Doctors Receiving Payments for Chikungunya
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Knoxville, TN | $1.3M | 19 |
| , M.D | Pediatrics | San Francisco, CA | $83,038 | 24 |
Ad
Manufacturing Companies
Product Information
- Type Product
- Total Payments $1.4M
- Total Doctors 1
- Transactions 43
About Chikungunya
Chikungunya is a product associated with $1.4M in payments to 1 healthcare providers, recorded across 43 transactions in the CMS Open Payments database. The primary manufacturer is Emergent BioSolutions Inc..
Payment data is available from 2022 to 2022. In 2022, $1.4M was paid across 43 transactions to 1 doctors.
The most common payment nature for Chikungunya is "Unspecified" ($1.4M, 100.0% of total).
Chikungunya is associated with 20 research studies, including "A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0328" ($197,467).